Science1 publisher2 min readPublished
Kennedy installs a neurologist with leucovorin ties atop the $2 billion autism committee
STAT reports that John Gaitanis, newly installed as chair of the federal committee that helps steer roughly $2 billion in autism research, has financial ties to leucovorin. STAT does not say what form that interest takes.
The Scientist · Science desk
What happened
- Health secretary Robert F. Kennedy Jr. has installed John Gaitanis, a pediatric neurologist, as the new chair of the Interagency Autism Coordinating Committee.
- STAT reported the appointment under a headline stating that the new federal autism committee head has financial ties to leucovorin.
- He also recently began a stint at the National Institutes of Health's child health institute, so he now holds a position inside the agency side as well.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- exposure Every priority the committee sets now runs through a chair whose financial position STAT has publicly tied to one candidate treatment.
- constraint An outside reader cannot judge how much weight to put on any review the committee blesses, even one that turns out to be correct, without the size and form of the interest on the record.
- decision The institute that just hired Gaitanis has to decide whether he recuses from leucovorin-related funding questions, and to say so before the committee's next priority-setting round.
- precedent If Vought's appointee commission is created, both the advisory layer and the grant review layer would answer to political appointment.
A financial interest is not evidence about a drug. Leucovorin's value in autism is the same either way, whoever holds a stake in it. What a stake changes is the standing of the person weighing the evidence. Whether the drug does anything for autistic children is a question for trial data, and it has to be answered on its own.
The committee Gaitanis now chairs does not run trials. It helps the federal government decide how to allocate roughly $2 billion in autism research [3]. Priority-setting sits upstream of any result: it determines which questions get funded and which comparisons get made at all.
Gaitanis is a pediatric neurologist [2], and according to STAT he is best known for co-founding Meadow Biosciences, a telehealth startup [5]. He also recently began a stint at the National Institutes of Health's child health institute [4]. He therefore sits on the advisory side of federal autism research and inside one of the agencies that pays for it [2][4]. STAT's newsletter introduced the change with a line about his predecessor: "Move over, Sylvia Fogel. It's John Gaitanis's turn to steer autism research." [6]
STAT's headline asserts the leucovorin tie [1]. The item does not give the form, size or date of the interest, or any federal position on the drug [10].
The same newsletter reported a separate fight over who controls federal research money. At an Oval Office meeting on Friday, budget director Russell Vought pushed to give political appointees more direct control over NIH funding, and, according to the Washington Post, encouraged Trump to sign an executive order establishing a commission of political appointees to review all grants coming out of NIH, saying current research is too "woke" [7]. Lawmakers in both parties then released statements warning that such a move would be "contrary to congressional intent" [8]. STAT's Anil Oza and Chelsea Cirruzzo reported that dispute [9].
The two threads are separate stories, but both turn on the same point: where a federal body decides what gets studied. For a reader outside the agency, the document that would settle the first one is a disclosure with recusal terms from the institute Gaitanis just joined [4].
What to watch
- Whether HHS or the NIH child health institute publishes a financial disclosure and recusal terms for Gaitanis.
- Whether leucovorin appears as a named priority in the committee's next research funding plan.
- Whether Trump signs the executive order creating an appointee commission over NIH grants after the bipartisan objections.